ArticleAdvances in therapy2025
Correction to: Effcacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Psoriasis and Special Body Area Involvement: Sub-analysis of a Randomized, Double-Blind, Multicenter Phase 3 Study.
Xia Li et al.PubMed ↗Publisher ↗
No numbers read from the abstract.